Abstract 63P
Background
Eribulin, a novel anti-tubulin agent, is a preferred treatment for patients (pts) with metastatic breast cancer (mBC) who have been pretreated with anthracycline and/or taxane-based therapy. Preclinical data suggest a potential synergistic effect of eribulin and platinum. However, clinical data on the combination for mBC are lacking. We evaluated eribulin plus platinum in pts with mBC.
Methods
This multi-center, real-world cohort study included pts with pre-treated metastatic triple- negative breast cancer (TNBC) or endocrine-refractory hormone receptor (HR) -positive, HER2 -negative mBC who received eribulin plus carboplatin (ErCb). Eribulin (1.4 mg/m2) and carboplatin (target AUC=2) were administered intravenously on days 1 and 8 of 21-day cycles. Progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR) and adverse events (AEs) were evaluated.
Results
From March 2022 to August 2023, 19 pts with TNBC and 11 with HR+HER2- mBC were included. Of the 19 pts with TNBC, 8 had an initial diagnosis of HR+HER2- disease. All 30 pts were female, with a median (range) age of 46 (31–60) years and had received a median of 2 (1–6) prior lines of therapy. Visceral metastases were present in 22 pts (73.3%). Best overall response, ORR, DCR, and PFS are shown in the table. Median overall survival was not reached. After a median of 6 cycles (range, 2–8) of ErCb, the most common grade 3–4 AEs were neutropenia (40.0%), leukopenia (23.3%), febrile neutropenia (10.0%), and anemia (3.3%). No grade 3–4 non-hematological AEs were observed. Table: 63P
| Patients, n (%) | |||
| Response | All patients (N=30) | TNBC group (N=19) | HR+HER2- group (N=11) |
| Complete response | 0 | 0 | 0 |
| Partial response | 19 (63.3) | 12 (63.2) | 7 (63.6) |
| Stable disease | 7 (23.3) | 4 (21.1) | 3 (27.3) |
| Progressive disease | 4 (13.3) | 3 (15.8) | 1 (9.1) |
| ORR | 19 (63.3) | 12 (63.2) | 7 (63.6) |
| DCR | 26 (86.6) | 16 (84.2) | 10 (91.0) |
| Median PFS, months (95% CI) | 5.0 (4.0-6.0) | 5.0 (1.3-8.7) | 5.6 (3.0-8.1) |
Conclusions
In this cohort of pts with heavily pre-treated HER2- mBC, ErCb demonstrated promising efficacy and a manageable safety profile. Further studies exploring this combination in earlier lines of treatment for mBC are warranted.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
592P - Treatment patterns and outcomes in patients with advanced non-small cell lung cancer with MET exon 14 skipping alterations in China
Presenter: Hanxiao Chen
Session: Poster Display
Resources:
Abstract
593P - MET TKIs in Asian patients (pts) with MET exon 14 skipping NSCLC: A matching-adjusted indirect comparison (MAIC)
Presenter: E-e Ke
Session: Poster Display
Resources:
Abstract
594P - The treatment pattern and clinical outcome in NSCLC patients with MET alteration: A retrospective real-world analysis in China
Presenter: Yongfeng Yu
Session: Poster Display
Resources:
Abstract
595P - Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC)
Presenter: Koichi Goto
Session: Poster Display
Resources:
Abstract
596P - Repotrectinib in patients (pts) from Asia and China with ROS1 fusion-positive (ROS1+) non-small cell lung cancer (NSCLC): Results from the phase I/II TRIDENT-1 trial
Presenter: Ross Soo
Session: Poster Display
Resources:
Abstract
597TiP - A phase I/II study to evaluate the safety and anti-tumor activity of JIN-A02 in patients with EGFR TKI-refractory, EGFR-mutant advanced NSCLC
Presenter: Sun Min Lim
Session: Poster Display
Resources:
Abstract
598TiP - Exploration of aumolertinib in first-line treatment for advanced non-small cell lung cancer patients of performance status 3 with EGFR mutations (19del and L858R)
Presenter: Haiyi Deng
Session: Poster Display
Resources:
Abstract
599TiP - A prospective study of savolitinib plus docetaxel in pretreated EGFR/ALK/ROS1/METex14m-wildtype advanced NSCLC patients with MET overexpression (FirstMET)
Presenter: Shuting Zhan
Session: Poster Display
Resources:
Abstract
600TiP - Phase III study of telisotuzumab vedotin (Teliso-V) vs docetaxel in pretreated c-Met overexpressing EGFR wildtype (WT) non-squamous (NSQ) locally advanced/metastatic non-small cell lung cancer (a/mNSCLC)
Presenter: Junko Tanizaki
Session: Poster Display
Resources:
Abstract
601P - Pembrolizumab in patients of Chinese descent with microsatellite instability-high/mismatch repair deficient advanced solid tumors: KEYNOTE-158
Presenter: Xiaohua Wu
Session: Poster Display
Resources:
Abstract